SCHEMBL1959015

SCHEMBL1959015

O=C(CC1CCOCC1)c1cc2cc(F)cnc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.38
HTT P42858 1/20 0.36
RORC P51449 1/20 0.35
LMNA P02545 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 1/20 0.35
PTGDR Q13258 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
MAPK1 P28482 1/20 0.34
NOD2 Q9HC29 1/20 0.33
NOD1 Q9Y239 1/20 0.33
FAAH O00519 1/20 0.33
PKM P14618 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
AOC2 O75106 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1959282 0.91 ALDH1A1 (0.36) LMNAALDH1A1MAPTPTGDRPTGDR2
SCHEMBL1964026 0.86 PIK3CG (0.37) RIPK1HTTLMNAALDH1A1PTGDR2
SCHEMBL1963039 0.85 LMNA (0.43) RIPK1HTTLMNAALDH1A1MAPT
SCHEMBL1958741 0.81 RECQL (0.35) HTTLMNAMAPK1SMN1; SMN2NPSR1
SCHEMBL1960658 0.81 RORC (0.42) RORC
SCHEMBL1962993 0.80 PDE5A (0.38) LMNAALDH1A1MAPTPTGDR2NOD2
SCHEMBL1962404 0.79 ALDH1A1 (0.41) HTTLMNAALDH1A1MAPTPTGDR2
SCHEMBL1959066 0.78 ALDH1A1 (0.39) LMNAALDH1A1MAPTPTGDRPTGDR2
SCHEMBL1958748 0.77 FKBP1A (0.38) HTTLMNAMAPTMAPK1PKM
SCHEMBL1960226 0.77 FKBP1A (0.38) HTTLMNAALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 RIPK1 1635/4885HTT 2485/4885RORC 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.